Kymera Therapeutics rose more than 21% after announcing completion of enrollment in its BROADEN2 Phase 2b trial for KT-621, a candidate for moderate to severe atopic dermatitis. The update removes a key development-risk milestone and signals the program is advancing on schedule. The move is likely stock-specific rather than sector-wide.
Kymera Therapeutics rose more than 21% after announcing completion of enrollment in its BROADEN2 Phase 2b trial for KT-621, a candidate for moderate to severe atopic dermatitis. The update removes a key development-risk milestone and signals the program is advancing on schedule. The move is likely stock-specific rather than sector-wide.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
